Featured Publications
Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials
Oikonomou EK, Spatz ES, Suchard MA, Khera R. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials. The Lancet Digital Health 2022, 4: e796-e805. PMID: 36307193, PMCID: PMC9768739, DOI: 10.1016/s2589-7500(22)00170-4.Peer-Reviewed Original ResearchConceptsSystolic blood pressure controlBlood pressure controlIntensive systolic blood pressure controlType 2 diabetesPressure controlCardiovascular benefitsClinical trialsMajor adverse cardiovascular eventsFirst major adverse cardiovascular eventLarge randomised clinical trialsACCORD-BP trialAdverse cardiovascular eventsRandomised clinical trialsSystolic blood pressureCox regression analysisTreatment effectsHazard ratio estimatesACCORD-BPBP trialCardiovascular eventsBlood pressurePrimary outcomeStandard treatmentBaseline variablesIndex patients
2017
Stem Cell Therapy for Congenital Heart Disease
Tsilimigras DI, Oikonomou EK, Moris D, Schizas D, Economopoulos KP, Mylonas KS. Stem Cell Therapy for Congenital Heart Disease. Circulation 2017, 136: 2373-2385. PMID: 29229621, DOI: 10.1161/circulationaha.117.029607.BooksConceptsCongenital heart diseaseCell therapyHeart diseaseClinical trialsGold standard treatment modalityHypoplastic left heart syndromePulmonary artery hypertensionRight ventricle dysfunctionStandard treatment modalityAlternative treatment optionLarge clinical studiesStem cell deliveryQuality of lifeCell-based therapeutic strategiesArtery hypertensionStem cell-based therapeutic strategiesVentricle dysfunctionSurgical palliationVolume overloadHeart syndromeSafety profileCell-seeded graftsCochrane LibraryTreatment optionsTreatment modalities